Patheon Adds Cell Based Assay Services

Patheon has launched cell based assay services to support biopharmaceutical product development. The new services will strengthen Patheon’s existing analytical capability in biopharmaceutical analysis, according to a company statement.

Cell based assays are a key technology used in determining the biological potency of biopharmaceuticals required for product licensing procedures. Biological potency analytics and the required supporting capabilities for tissue culture, such as assessment of cell viability and production of master and working cell banks, will take place at Patheon’s Swindon, UK facility. This will enable all the analytical needs for biopharmaceutical product development to be completed in one location.

Wes Wheeler, president and chief executive officer of Patheon, commented, “Expanding the services provided through using cell based assays at our Swindon facility, is a testament to the commitment Patheon has to enhancing and growing the Pharmaceutical Development Services provided to our customers. This new capability allows us to better meet the needs of customers in the early stages of drug development.”

The facility will be managed and supported by a team of scientists with approximately 18 years of combined experience in tissue culture and cell based assays. The facility will be fully available for use at the end of May.